| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus | 45 | 2022 | 445 | 8.650 |
Why?
|
| Hypoglycemic Agents | 23 | 2021 | 247 | 3.570 |
Why?
|
| Diabetes Mellitus, Type 2 | 23 | 2022 | 677 | 3.410 |
Why?
|
| Medication Adherence | 23 | 2020 | 235 | 3.010 |
Why?
|
| Prediabetic State | 6 | 2019 | 63 | 2.280 |
Why?
|
| Humans | 138 | 2023 | 16832 | 2.280 |
Why?
|
| Postal Service | 7 | 2020 | 72 | 2.030 |
Why?
|
| Hypertension | 20 | 2019 | 475 | 2.010 |
Why?
|
| Cardiovascular Diseases | 14 | 2021 | 520 | 1.920 |
Why?
|
| Physician-Patient Relations | 15 | 2017 | 169 | 1.880 |
Why?
|
| Delivery of Health Care, Integrated | 7 | 2023 | 515 | 1.860 |
Why?
|
| Antihypertensive Agents | 15 | 2015 | 157 | 1.760 |
Why?
|
| Female | 95 | 2022 | 12193 | 1.740 |
Why?
|
| California | 46 | 2023 | 2244 | 1.710 |
Why?
|
| Telephone | 8 | 2017 | 157 | 1.700 |
Why?
|
| Patient Compliance | 11 | 2014 | 262 | 1.650 |
Why?
|
| Adult | 67 | 2023 | 7255 | 1.630 |
Why?
|
| Male | 81 | 2021 | 9556 | 1.610 |
Why?
|
| Aged | 62 | 2021 | 5901 | 1.520 |
Why?
|
| Retrospective Studies | 32 | 2023 | 2463 | 1.510 |
Why?
|
| Blood Glucose | 9 | 2022 | 315 | 1.500 |
Why?
|
| Pharmaceutical Services | 5 | 2019 | 37 | 1.470 |
Why?
|
| Health Promotion | 10 | 2017 | 277 | 1.410 |
Why?
|
| Middle Aged | 70 | 2021 | 7515 | 1.390 |
Why?
|
| Quality Improvement | 6 | 2017 | 184 | 1.220 |
Why?
|
| Delivery of Health Care | 6 | 2020 | 374 | 1.210 |
Why?
|
| Health Maintenance Organizations | 16 | 2013 | 358 | 1.190 |
Why?
|
| United States | 41 | 2022 | 3858 | 1.190 |
Why?
|
| Glycated Hemoglobin A | 14 | 2022 | 176 | 1.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2017 | 155 | 1.130 |
Why?
|
| Quality of Health Care | 10 | 2020 | 249 | 1.090 |
Why?
|
| Insurance, Pharmaceutical Services | 5 | 2014 | 22 | 1.090 |
Why?
|
| Aged, 80 and over | 22 | 2021 | 1887 | 1.020 |
Why?
|
| Primary Health Care | 14 | 2017 | 693 | 0.970 |
Why?
|
| Patient-Centered Care | 6 | 2016 | 185 | 0.970 |
Why?
|
| Mentoring | 2 | 2017 | 29 | 0.970 |
Why?
|
| Healthcare Disparities | 3 | 2020 | 213 | 0.970 |
Why?
|
| Chronic Disease | 12 | 2010 | 382 | 0.940 |
Why?
|
| Practice Patterns, Physicians' | 10 | 2017 | 290 | 0.910 |
Why?
|
| Occupational Health Services | 2 | 2015 | 12 | 0.840 |
Why?
|
| Medicare Part D | 5 | 2010 | 17 | 0.840 |
Why?
|
| Cross-Sectional Studies | 19 | 2015 | 1233 | 0.810 |
Why?
|
| Medicare | 2 | 2015 | 188 | 0.800 |
Why?
|
| Health Services Research | 12 | 2019 | 180 | 0.780 |
Why?
|
| Adolescent | 21 | 2023 | 3464 | 0.780 |
Why?
|
| Risk Factors | 23 | 2021 | 3108 | 0.770 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 56 | 0.760 |
Why?
|
| Electronic Health Records | 10 | 2018 | 702 | 0.750 |
Why?
|
| Feeding and Eating Disorders | 1 | 2022 | 16 | 0.750 |
Why?
|
| Health Priorities | 3 | 2019 | 21 | 0.750 |
Why?
|
| Leadership | 2 | 2022 | 34 | 0.740 |
Why?
|
| Delayed Diagnosis | 2 | 2020 | 21 | 0.740 |
Why?
|
| Patient Satisfaction | 12 | 2017 | 186 | 0.730 |
Why?
|
| Comparative Effectiveness Research | 4 | 2015 | 60 | 0.730 |
Why?
|
| Managed Care Programs | 6 | 2010 | 275 | 0.680 |
Why?
|
| Program Evaluation | 7 | 2015 | 211 | 0.680 |
Why?
|
| European Continental Ancestry Group | 5 | 2020 | 400 | 0.680 |
Why?
|
| Logistic Models | 17 | 2019 | 796 | 0.680 |
Why?
|
| Health Services Accessibility | 6 | 2022 | 262 | 0.670 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2015 | 353 | 0.660 |
Why?
|
| Uterine Hemorrhage | 1 | 2020 | 9 | 0.650 |
Why?
|
| Pharmacy | 1 | 2020 | 12 | 0.640 |
Why?
|
| Endometrial Neoplasms | 1 | 2020 | 37 | 0.640 |
Why?
|
| Outcome and Process Assessment (Health Care) | 7 | 2016 | 85 | 0.640 |
Why?
|
| Mental Disorders | 2 | 2020 | 248 | 0.630 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2020 | 116 | 0.620 |
Why?
|
| Women's Health | 3 | 2022 | 178 | 0.610 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.610 |
Why?
|
| Physicians, Family | 6 | 2004 | 35 | 0.610 |
Why?
|
| Health Services for the Aged | 1 | 2019 | 14 | 0.600 |
Why?
|
| Smoking Cessation | 2 | 2020 | 140 | 0.600 |
Why?
|
| Pandemics | 2 | 2020 | 289 | 0.590 |
Why?
|
| Quality Assurance, Health Care | 7 | 2010 | 117 | 0.570 |
Why?
|
| Quality Indicators, Health Care | 9 | 2017 | 126 | 0.560 |
Why?
|
| Glycemic Index | 1 | 2018 | 17 | 0.560 |
Why?
|
| Medicare Part C | 1 | 2018 | 11 | 0.560 |
Why?
|
| Research Personnel | 2 | 2015 | 24 | 0.560 |
Why?
|
| Cholesterol, LDL | 6 | 2017 | 113 | 0.540 |
Why?
|
| Outcome Assessment (Health Care) | 6 | 2016 | 199 | 0.540 |
Why?
|
| Weight Loss | 3 | 2017 | 302 | 0.540 |
Why?
|
| Asian Continental Ancestry Group | 2 | 2020 | 69 | 0.530 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2018 | 41 | 0.520 |
Why?
|
| Hyperlipidemias | 5 | 2011 | 43 | 0.520 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2017 | 80 | 0.520 |
Why?
|
| Insurance Coverage | 4 | 2010 | 102 | 0.520 |
Why?
|
| Incidence | 9 | 2022 | 1229 | 0.500 |
Why?
|
| Comorbidity | 7 | 2019 | 516 | 0.500 |
Why?
|
| Health Policy | 5 | 2017 | 101 | 0.500 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2017 | 51 | 0.500 |
Why?
|
| Blood Pressure | 11 | 2017 | 278 | 0.490 |
Why?
|
| Drug Costs | 4 | 2013 | 32 | 0.490 |
Why?
|
| Prescription Drugs | 2 | 2014 | 29 | 0.490 |
Why?
|
| Motivational Interviewing | 1 | 2016 | 29 | 0.480 |
Why?
|
| Patient Participation | 3 | 2016 | 120 | 0.480 |
Why?
|
| Health Care Surveys | 8 | 2017 | 201 | 0.470 |
Why?
|
| Depression | 5 | 2015 | 479 | 0.470 |
Why?
|
| Treatment Outcome | 12 | 2017 | 1098 | 0.470 |
Why?
|
| Mass Media | 1 | 2015 | 14 | 0.460 |
Why?
|
| Young Adult | 17 | 2021 | 2456 | 0.460 |
Why?
|
| Obesity | 4 | 2017 | 811 | 0.460 |
Why?
|
| Electronic Mail | 1 | 2015 | 52 | 0.450 |
Why?
|
| Total Quality Management | 2 | 2017 | 13 | 0.450 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 553 | 0.430 |
Why?
|
| Physicians, Women | 4 | 2009 | 10 | 0.430 |
Why?
|
| Emergency Service, Hospital | 2 | 2019 | 393 | 0.430 |
Why?
|
| Translational Medical Research | 2 | 2015 | 24 | 0.420 |
Why?
|
| Esophageal Neoplasms | 3 | 2010 | 110 | 0.410 |
Why?
|
| Contraception | 4 | 2018 | 24 | 0.410 |
Why?
|
| Barrett Esophagus | 3 | 2010 | 107 | 0.410 |
Why?
|
| Insurance Claim Review | 6 | 2020 | 48 | 0.400 |
Why?
|
| Cohort Studies | 10 | 2020 | 2396 | 0.400 |
Why?
|
| Diabetes, Gestational | 4 | 2015 | 330 | 0.400 |
Why?
|
| Life Style | 6 | 2019 | 305 | 0.390 |
Why?
|
| Employee Incentive Plans | 1 | 2013 | 4 | 0.380 |
Why?
|
| Pharmacies | 2 | 2015 | 9 | 0.370 |
Why?
|
| Disease Management | 4 | 2006 | 106 | 0.360 |
Why?
|
| African Continental Ancestry Group | 1 | 2013 | 117 | 0.360 |
Why?
|
| Choice Behavior | 7 | 2016 | 44 | 0.360 |
Why?
|
| Health Behavior | 2 | 2013 | 332 | 0.360 |
Why?
|
| Family Planning Services | 3 | 2016 | 20 | 0.350 |
Why?
|
| Self Care | 3 | 2007 | 139 | 0.350 |
Why?
|
| Communication | 6 | 2016 | 183 | 0.350 |
Why?
|
| Patient Care Management | 2 | 2009 | 22 | 0.350 |
Why?
|
| Counseling | 4 | 2017 | 170 | 0.340 |
Why?
|
| Provider-Sponsored Organizations | 3 | 2005 | 3 | 0.330 |
Why?
|
| African Americans | 4 | 2020 | 394 | 0.330 |
Why?
|
| Ambulatory Care Facilities | 1 | 2011 | 60 | 0.320 |
Why?
|
| Diabetes Complications | 5 | 2021 | 93 | 0.320 |
Why?
|
| Systems Theory | 1 | 2010 | 2 | 0.320 |
Why?
|
| Race Relations | 1 | 2009 | 1 | 0.310 |
Why?
|
| Hawaii | 2 | 2020 | 62 | 0.310 |
Why?
|
| Community-Based Participatory Research | 1 | 2010 | 45 | 0.310 |
Why?
|
| Needs Assessment | 2 | 2020 | 64 | 0.300 |
Why?
|
| Multivariate Analysis | 10 | 2015 | 489 | 0.300 |
Why?
|
| Risk Reduction Behavior | 3 | 2015 | 97 | 0.290 |
Why?
|
| Treatment Refusal | 2 | 2008 | 30 | 0.290 |
Why?
|
| Registries | 5 | 2012 | 449 | 0.270 |
Why?
|
| Body Mass Index | 6 | 2017 | 925 | 0.270 |
Why?
|
| Adenocarcinoma | 2 | 2010 | 160 | 0.270 |
Why?
|
| Socioeconomic Factors | 5 | 2016 | 571 | 0.270 |
Why?
|
| Ethnic Groups | 5 | 2020 | 418 | 0.260 |
Why?
|
| Guideline Adherence | 2 | 2010 | 155 | 0.260 |
Why?
|
| Models, Statistical | 4 | 2018 | 164 | 0.260 |
Why?
|
| Contraception Behavior | 3 | 2016 | 16 | 0.260 |
Why?
|
| Accountable Care Organizations | 2 | 2017 | 5 | 0.260 |
Why?
|
| Pregnancy | 7 | 2018 | 1555 | 0.260 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2007 | 41 | 0.250 |
Why?
|
| Cost Sharing | 2 | 2018 | 28 | 0.250 |
Why?
|
| Gynecology | 3 | 2011 | 21 | 0.240 |
Why?
|
| Hispanic Americans | 3 | 2020 | 350 | 0.240 |
Why?
|
| Odds Ratio | 5 | 2015 | 569 | 0.240 |
Why?
|
| Qualitative Research | 5 | 2019 | 288 | 0.240 |
Why?
|
| Professional-Patient Relations | 3 | 2016 | 45 | 0.230 |
Why?
|
| Sex Factors | 5 | 2015 | 560 | 0.230 |
Why?
|
| Preventive Health Services | 2 | 2004 | 142 | 0.230 |
Why?
|
| Time Factors | 8 | 2021 | 989 | 0.230 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 1058 | 0.220 |
Why?
|
| Propensity Score | 2 | 2016 | 78 | 0.220 |
Why?
|
| Prevalence | 2 | 2020 | 785 | 0.220 |
Why?
|
| Monitoring, Physiologic | 2 | 2015 | 35 | 0.220 |
Why?
|
| Decision Making | 2 | 2017 | 164 | 0.210 |
Why?
|
| Efficiency, Organizational | 3 | 2017 | 25 | 0.210 |
Why?
|
| Gastroesophageal Reflux | 3 | 2009 | 73 | 0.200 |
Why?
|
| Quality of Life | 3 | 2016 | 477 | 0.200 |
Why?
|
| Reminder Systems | 1 | 2004 | 76 | 0.200 |
Why?
|
| Adiposity | 1 | 2014 | 69 | 0.200 |
Why?
|
| Patient Care Team | 4 | 2012 | 98 | 0.200 |
Why?
|
| Surveys and Questionnaires | 10 | 2016 | 1204 | 0.200 |
Why?
|
| Health Care Reform | 2 | 2015 | 19 | 0.190 |
Why?
|
| Risk | 2 | 2020 | 453 | 0.190 |
Why?
|
| Databases, Factual | 5 | 2015 | 294 | 0.190 |
Why?
|
| Insulin | 3 | 2020 | 181 | 0.190 |
Why?
|
| Housing | 1 | 2023 | 38 | 0.190 |
Why?
|
| Attitude to Health | 2 | 2004 | 142 | 0.190 |
Why?
|
| Algorithms | 2 | 2014 | 210 | 0.190 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2015 | 189 | 0.180 |
Why?
|
| Models, Organizational | 3 | 2013 | 50 | 0.180 |
Why?
|
| Dietary Fiber | 2 | 2010 | 60 | 0.180 |
Why?
|
| Hypolipidemic Agents | 4 | 2010 | 38 | 0.180 |
Why?
|
| Contraceptive Agents | 3 | 2018 | 6 | 0.180 |
Why?
|
| Group Practice | 4 | 2005 | 20 | 0.180 |
Why?
|
| Precancerous Conditions | 2 | 2009 | 45 | 0.170 |
Why?
|
| Insulin, Short-Acting | 1 | 2021 | 3 | 0.170 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2014 | 206 | 0.170 |
Why?
|
| Focus Groups | 2 | 2019 | 140 | 0.170 |
Why?
|
| Insulin, Long-Acting | 1 | 2021 | 10 | 0.170 |
Why?
|
| Independent Practice Associations | 4 | 2005 | 4 | 0.170 |
Why?
|
| Yoga | 1 | 2011 | 25 | 0.160 |
Why?
|
| Remote Consultation | 1 | 2020 | 9 | 0.160 |
Why?
|
| Fear | 1 | 2020 | 14 | 0.160 |
Why?
|
| RNA, Viral | 1 | 2020 | 66 | 0.160 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 19 | 0.160 |
Why?
|
| Micronutrients | 1 | 2010 | 9 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2021 | 55 | 0.160 |
Why?
|
| Hypokalemia | 1 | 2020 | 1 | 0.160 |
Why?
|
| Diet | 2 | 2014 | 349 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 36 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 23 | 0.160 |
Why?
|
| Clinical Competence | 3 | 2010 | 107 | 0.160 |
Why?
|
| Patient Admission | 2 | 2019 | 58 | 0.160 |
Why?
|
| Hyperkalemia | 1 | 2020 | 14 | 0.160 |
Why?
|
| Age Factors | 3 | 2018 | 814 | 0.160 |
Why?
|
| Insulin, Regular, Human | 1 | 2020 | 5 | 0.150 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2020 | 4 | 0.150 |
Why?
|
| Heart Failure | 4 | 2020 | 403 | 0.150 |
Why?
|
| Child | 2 | 2022 | 2433 | 0.150 |
Why?
|
| Syncope | 1 | 2019 | 11 | 0.150 |
Why?
|
| Drug Therapy | 2 | 2009 | 16 | 0.150 |
Why?
|
| Women | 1 | 1999 | 11 | 0.150 |
Why?
|
| Nurse Practitioners | 1 | 1999 | 18 | 0.150 |
Why?
|
| Social Work | 1 | 2019 | 15 | 0.150 |
Why?
|
| Hypoglycemia | 1 | 2019 | 48 | 0.140 |
Why?
|
| Meat | 1 | 2009 | 27 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 84 | 0.140 |
Why?
|
| Motor Activity | 3 | 2015 | 196 | 0.140 |
Why?
|
| Hip Fractures | 1 | 2019 | 72 | 0.140 |
Why?
|
| Colorado | 2 | 2017 | 171 | 0.140 |
Why?
|
| Dietary Fats | 1 | 2009 | 88 | 0.140 |
Why?
|
| Hospitalization | 3 | 2022 | 816 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2018 | 81 | 0.140 |
Why?
|
| Physician's Role | 3 | 2017 | 25 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2013 | 210 | 0.130 |
Why?
|
| Pharmacists | 3 | 2014 | 53 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2016 | 352 | 0.130 |
Why?
|
| Spouses | 1 | 2017 | 9 | 0.130 |
Why?
|
| Work Performance | 1 | 2017 | 1 | 0.130 |
Why?
|
| Employee Performance Appraisal | 1 | 2017 | 5 | 0.130 |
Why?
|
| Social Support | 3 | 2019 | 195 | 0.130 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2017 | 55 | 0.120 |
Why?
|
| Disclosure | 1 | 2016 | 15 | 0.120 |
Why?
|
| Deductibles and Coinsurance | 2 | 2014 | 31 | 0.120 |
Why?
|
| Smoking | 1 | 2008 | 373 | 0.120 |
Why?
|
| Diabetic Neuropathies | 1 | 2016 | 10 | 0.120 |
Why?
|
| Office Visits | 1 | 2016 | 78 | 0.120 |
Why?
|
| Longitudinal Studies | 4 | 2018 | 653 | 0.120 |
Why?
|
| Physicians, Primary Care | 1 | 2016 | 63 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 48 | 0.120 |
Why?
|
| Neoplasms | 1 | 2020 | 447 | 0.120 |
Why?
|
| Self Report | 2 | 2015 | 248 | 0.110 |
Why?
|
| Glucose Tolerance Test | 1 | 2015 | 108 | 0.110 |
Why?
|
| Career Mobility | 1 | 2015 | 4 | 0.110 |
Why?
|
| Research Support as Topic | 1 | 2015 | 15 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 2 | 2014 | 67 | 0.110 |
Why?
|
| Machine Learning | 1 | 2016 | 60 | 0.110 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 20 | 0.110 |
Why?
|
| Asian Americans | 2 | 2010 | 146 | 0.110 |
Why?
|
| Postpartum Period | 1 | 2015 | 89 | 0.110 |
Why?
|
| Safety-net Providers | 1 | 2015 | 52 | 0.110 |
Why?
|
| Patient Education as Topic | 3 | 2014 | 186 | 0.110 |
Why?
|
| Social Networking | 1 | 2014 | 19 | 0.110 |
Why?
|
| Drug Utilization | 1 | 2015 | 112 | 0.110 |
Why?
|
| Behavior Therapy | 1 | 2015 | 121 | 0.110 |
Why?
|
| Social Environment | 1 | 2014 | 77 | 0.110 |
Why?
|
| Diabetic Nephropathies | 1 | 2014 | 24 | 0.100 |
Why?
|
| Insurance, Health | 1 | 2015 | 167 | 0.100 |
Why?
|
| Medicaid | 1 | 2015 | 189 | 0.100 |
Why?
|
| Health Systems Plans | 1 | 2013 | 3 | 0.100 |
Why?
|
| Physician Incentive Plans | 2 | 2004 | 4 | 0.100 |
Why?
|
| Mass Screening | 2 | 2013 | 670 | 0.100 |
Why?
|
| Vital Signs | 1 | 2013 | 12 | 0.100 |
Why?
|
| Blood Pressure Determination | 2 | 2011 | 57 | 0.100 |
Why?
|
| Early Medical Intervention | 1 | 2013 | 11 | 0.100 |
Why?
|
| Trust | 3 | 2009 | 33 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2013 | 14 | 0.100 |
Why?
|
| Primary Prevention | 2 | 2012 | 60 | 0.100 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 197 | 0.100 |
Why?
|
| State Health Plans | 1 | 2013 | 30 | 0.100 |
Why?
|
| Cooperative Behavior | 2 | 2010 | 84 | 0.100 |
Why?
|
| Glucose Intolerance | 1 | 2013 | 45 | 0.090 |
Why?
|
| Obstetrics | 2 | 2011 | 20 | 0.090 |
Why?
|
| Cerebrovascular Disorders | 1 | 2012 | 29 | 0.090 |
Why?
|
| Drug Resistance | 1 | 2012 | 19 | 0.090 |
Why?
|
| Weight Gain | 1 | 2014 | 167 | 0.090 |
Why?
|
| Research Design | 4 | 2016 | 319 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 311 | 0.090 |
Why?
|
| Anxiety | 1 | 2012 | 154 | 0.090 |
Why?
|
| Coronary Disease | 1 | 2012 | 125 | 0.090 |
Why?
|
| Health Care Costs | 4 | 2015 | 192 | 0.080 |
Why?
|
| Electronic Prescribing | 1 | 2010 | 7 | 0.080 |
Why?
|
| Depressive Disorder | 1 | 2012 | 177 | 0.080 |
Why?
|
| Cost Control | 1 | 2010 | 12 | 0.080 |
Why?
|
| Reimbursement, Incentive | 1 | 2010 | 19 | 0.080 |
Why?
|
| Drugs, Generic | 1 | 2010 | 6 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 129 | 0.080 |
Why?
|
| Fees, Pharmaceutical | 1 | 2009 | 2 | 0.080 |
Why?
|
| Diabetic Angiopathies | 1 | 2010 | 33 | 0.080 |
Why?
|
| Language | 1 | 2010 | 51 | 0.080 |
Why?
|
| Research | 1 | 2010 | 53 | 0.080 |
Why?
|
| Reimbursement Mechanisms | 1 | 2009 | 15 | 0.080 |
Why?
|
| Causality | 1 | 2009 | 32 | 0.080 |
Why?
|
| Patients | 1 | 2009 | 29 | 0.080 |
Why?
|
| Specialization | 2 | 1999 | 18 | 0.070 |
Why?
|
| Observation | 1 | 2009 | 20 | 0.070 |
Why?
|
| Patient Care | 1 | 2009 | 31 | 0.070 |
Why?
|
| Diabetic Retinopathy | 2 | 2010 | 17 | 0.070 |
Why?
|
| Social Class | 1 | 2009 | 106 | 0.070 |
Why?
|
| Exercise | 1 | 2013 | 513 | 0.070 |
Why?
|
| Cluster Analysis | 3 | 2015 | 88 | 0.070 |
Why?
|
| Confounding Factors (Epidemiology) | 3 | 2014 | 77 | 0.070 |
Why?
|
| Peptic Ulcer | 2 | 1998 | 13 | 0.070 |
Why?
|
| Medical Audit | 1 | 2008 | 31 | 0.070 |
Why?
|
| Mammography | 2 | 2010 | 141 | 0.070 |
Why?
|
| Overweight | 2 | 2014 | 262 | 0.070 |
Why?
|
| Health Facility Administration | 1 | 2007 | 1 | 0.070 |
Why?
|
| Decision Making, Organizational | 1 | 2007 | 3 | 0.070 |
Why?
|
| Information Storage and Retrieval | 1 | 2007 | 17 | 0.070 |
Why?
|
| Health Surveys | 1 | 2007 | 226 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 3 | 2014 | 76 | 0.060 |
Why?
|
| Ambulatory Care | 4 | 2010 | 205 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2009 | 995 | 0.060 |
Why?
|
| Practice Management, Medical | 1 | 2005 | 6 | 0.060 |
Why?
|
| Health Status Indicators | 1 | 2005 | 58 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 657 | 0.060 |
Why?
|
| Information Services | 1 | 2004 | 7 | 0.050 |
Why?
|
| Adipose Tissue | 1 | 2014 | 63 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 410 | 0.050 |
Why?
|
| Albuminuria | 2 | 2014 | 39 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2014 | 84 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 346 | 0.050 |
Why?
|
| Linear Models | 2 | 2017 | 187 | 0.050 |
Why?
|
| Clinical Protocols | 2 | 2016 | 38 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2016 | 1186 | 0.050 |
Why?
|
| Information Systems | 1 | 2003 | 15 | 0.050 |
Why?
|
| Interviews as Topic | 2 | 2008 | 305 | 0.050 |
Why?
|
| Medicine | 2 | 1999 | 15 | 0.050 |
Why?
|
| Benchmarking | 2 | 2017 | 32 | 0.050 |
Why?
|
| Women, Working | 1 | 2002 | 4 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2005 | 1047 | 0.040 |
Why?
|
| Influenza, Human | 1 | 2004 | 292 | 0.040 |
Why?
|
| Medically Underserved Area | 1 | 2011 | 12 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 16 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2011 | 108 | 0.040 |
Why?
|
| Fruit | 1 | 2010 | 79 | 0.040 |
Why?
|
| Potassium | 1 | 2020 | 14 | 0.040 |
Why?
|
| Vegetables | 1 | 2010 | 88 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2020 | 92 | 0.040 |
Why?
|
| Financing, Personal | 2 | 2010 | 18 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2020 | 127 | 0.040 |
Why?
|
| Economics, Medical | 1 | 1999 | 4 | 0.040 |
Why?
|
| Disease Progression | 1 | 2010 | 252 | 0.040 |
Why?
|
| Trans Fatty Acids | 1 | 2009 | 4 | 0.040 |
Why?
|
| Cooking | 1 | 2009 | 17 | 0.040 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2009 | 18 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2010 | 113 | 0.040 |
Why?
|
| Health Expenditures | 2 | 2010 | 69 | 0.040 |
Why?
|
| Geography | 1 | 2008 | 39 | 0.040 |
Why?
|
| Drug Prescriptions | 2 | 2010 | 137 | 0.030 |
Why?
|
| Animals | 1 | 2009 | 237 | 0.030 |
Why?
|
| Helicobacter Infections | 1 | 1998 | 19 | 0.030 |
Why?
|
| Helicobacter pylori | 1 | 1998 | 21 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2008 | 207 | 0.030 |
Why?
|
| Gastritis | 1 | 1997 | 2 | 0.030 |
Why?
|
| Dyspepsia | 1 | 1997 | 5 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 215 | 0.030 |
Why?
|
| Workflow | 1 | 2017 | 11 | 0.030 |
Why?
|
| Stroke | 1 | 2020 | 297 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 913 | 0.030 |
Why?
|
| Checklist | 1 | 2016 | 13 | 0.030 |
Why?
|
| Patient Safety | 1 | 2017 | 37 | 0.030 |
Why?
|
| Hospitals | 1 | 1997 | 69 | 0.030 |
Why?
|
| San Francisco | 1 | 2016 | 54 | 0.030 |
Why?
|
| Regression Analysis | 3 | 2004 | 261 | 0.030 |
Why?
|
| Automation | 1 | 2016 | 22 | 0.030 |
Why?
|
| Aging | 1 | 1997 | 146 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2008 | 298 | 0.030 |
Why?
|
| Pregnancy, High-Risk | 1 | 1995 | 4 | 0.030 |
Why?
|
| Fetal Death | 1 | 1995 | 7 | 0.030 |
Why?
|
| Maternal Age | 1 | 1995 | 73 | 0.030 |
Why?
|
| Public Health | 1 | 2016 | 80 | 0.030 |
Why?
|
| Epidemiologic Factors | 1 | 2015 | 3 | 0.030 |
Why?
|
| Tape Recording | 1 | 2014 | 5 | 0.030 |
Why?
|
| Information Seeking Behavior | 1 | 2014 | 10 | 0.030 |
Why?
|
| Biostatistics | 1 | 2014 | 11 | 0.030 |
Why?
|
| Selection Bias | 1 | 2014 | 16 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2017 | 244 | 0.030 |
Why?
|
| Probability | 1 | 2014 | 66 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2014 | 44 | 0.030 |
Why?
|
| Creatinine | 1 | 2014 | 67 | 0.030 |
Why?
|
| Poverty | 1 | 2015 | 167 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2014 | 21 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 104 | 0.030 |
Why?
|
| Postnatal Care | 1 | 2014 | 20 | 0.030 |
Why?
|
| Data Collection | 2 | 2007 | 223 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2013 | 21 | 0.030 |
Why?
|
| Diffusion of Innovation | 2 | 2004 | 33 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2014 | 157 | 0.020 |
Why?
|
| Sulfonylurea Compounds | 1 | 2013 | 30 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2013 | 11 | 0.020 |
Why?
|
| Metformin | 1 | 2013 | 49 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2013 | 68 | 0.020 |
Why?
|
| Fasting | 1 | 2013 | 45 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2013 | 66 | 0.020 |
Why?
|
| Community Health Workers | 1 | 2012 | 10 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2014 | 123 | 0.020 |
Why?
|
| Diuretics | 1 | 2012 | 17 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 110 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2012 | 42 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 229 | 0.020 |
Why?
|
| Veterans | 1 | 2012 | 143 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 66 | 0.020 |
Why?
|
| Multilingualism | 1 | 2010 | 7 | 0.020 |
Why?
|
| Frustration | 1 | 2010 | 2 | 0.020 |
Why?
|
| Insurance, Medigap | 1 | 2009 | 1 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 89 | 0.020 |
Why?
|
| Biomarkers | 1 | 2010 | 284 | 0.020 |
Why?
|
| Systole | 1 | 2009 | 21 | 0.020 |
Why?
|
| Asthma | 2 | 2003 | 375 | 0.020 |
Why?
|
| Physicians | 1 | 2010 | 114 | 0.020 |
Why?
|
| Continental Population Groups | 1 | 2010 | 255 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2010 | 130 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 68 | 0.020 |
Why?
|
| Empirical Research | 1 | 2005 | 1 | 0.010 |
Why?
|
| Financial Management | 1 | 2005 | 2 | 0.010 |
Why?
|
| Organizational Culture | 1 | 2005 | 16 | 0.010 |
Why?
|
| Learning | 1 | 2005 | 18 | 0.010 |
Why?
|
| Information Dissemination | 1 | 2004 | 43 | 0.010 |
Why?
|
| Perception | 1 | 2003 | 53 | 0.010 |
Why?
|
| Case Management | 1 | 2002 | 27 | 0.010 |
Why?
|
| Medical Informatics | 1 | 2002 | 34 | 0.010 |
Why?
|
| England | 1 | 2002 | 3 | 0.010 |
Why?
|
| Efficiency | 1 | 2002 | 11 | 0.010 |
Why?
|
| Australia | 1 | 2002 | 26 | 0.010 |
Why?
|
| Canada | 1 | 2002 | 74 | 0.010 |
Why?
|
| Family Practice | 1 | 2002 | 40 | 0.010 |
Why?
|
| Workload | 1 | 2002 | 26 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2002 | 58 | 0.010 |
Why?
|
| Health Facility Environment | 1 | 1999 | 2 | 0.010 |
Why?
|
| Poisson Distribution | 1 | 1999 | 84 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1998 | 58 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 1999 | 147 | 0.010 |
Why?
|
| Quebec | 1 | 1995 | 2 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 1995 | 18 | 0.010 |
Why?
|
| Infant Mortality | 1 | 1995 | 14 | 0.010 |
Why?
|
| Parity | 1 | 1995 | 53 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 1995 | 202 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1995 | 828 | 0.010 |
Why?
|